Alkermes appoints Mark Stejbach CCO
This article was originally published in Scrip
Biopharmaceutical company Alkermes has appointed Mark Stejbach its first chief commercial officer. Mr Stejbach most recently served as chief commercial officer at Tengion, and was previously vice-president of managed care marketing at Merck & Co. He has 25 years' experience in sales and marketing in the biotech and pharmaceutical industries.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.